Industrial Production of Therapeutic Proteins: Cell Lines, Cell Culture, and Purification

Zhu, Marie M.; Mollet, Mike; Hubert, René

doi:10.1007/978-1-4614-4259-2_32

Cited by 10 publications

(11 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…high-expression sublines that were derived from these two cell lines. 99 In order to enhance the efficiency of the production of biopharmaceuticals, one must increase the production rate of the target protein in a culture medium that contains none or a minimal amount of ingredients of biological origin, like serum, because they significantly hamper the process of product purification. Research in this direction has been conducted to efficiently optimize the medium's composition, for example, by means of approaches that are based on the monitoring of changes in the concentration of the medium components and byproducts in the culture, 100 as well as genomics-and proteomics-based Composition is undefined; thus, there is a large lot-to-lot variation.…”

Section: Improvements To Basal Media (1970-)mentioning

confidence: 99%

Animal‐cell culture media: History, characteristics, and current issues

Yao

Asayama

2017

Reprod Medicine & Biology

374

278

View full text Add to dashboard Cite

BackgroundCell culture technology has spread prolifically within a century, a variety of culture media has been designed. This review goes through the history, characteristics and current issues of animal‐cell culture media.MethodsA literature search was performed on PubMed and Google Scholar between 1880 and May 2016 using appropriate keywords.ResultsAt the dawn of cell culture technology, the major components of media were naturally derived products such as serum. The field then gradually shifted to the use of chemical‐based synthetic media because naturally derived ingredients have their disadvantages such as large batch‐to‐batch variation. Today, industrially important cells can be cultured in synthetic media. Nevertheless, the combinations and concentrations of the components in these media remain to be optimized. In addition, serum‐containing media are still in general use in the field of basic research. In the fields of assisted reproductive technologies and regenerative medicine, some of the medium components are naturally derived in nearly all instances.ConclusionsFurther improvements of culture media are desirable, which will certainly contribute to a reduction in the experimental variation, enhance productivity among biopharmaceuticals, improve treatment outcomes of assisted reproductive technologies, and facilitate implementation and popularization of regenerative medicine.

show abstract

Section: Improvements To Basal Media (1970-)mentioning

confidence: 99%

Animal‐cell culture media: History, characteristics, and current issues

Yao

Asayama

2017

Reprod Medicine & Biology

374

278

View full text Add to dashboard Cite

show abstract

“…The supply of oxygen to the cells can easily be the limiting factor in achieving high cell densities (Ozturk, 1996 ; Zhu et al, 2017 ). The design of the mass‐flow controller and sparger require consideration.…”

Section: Resultsmentioning

confidence: 99%

The design basis for the integrated and continuous biomanufacturing framework

Coffman

Bibbo²,

Brower

et al. 2021

Biotech & Bioengineering

View full text Add to dashboard Cite

An 8 ton per year manufacturing facility is described based on the framework for integrated and continuous bioprocessing (ICB) common to all known biopharmaceutical implementations. While the output of this plant rivals some of the largest fed‐batch plants in the world, the equipment inside the plant is relatively small: the plant consists of four 2000 L single‐use bioreactors and has a maximum flow rate of 13 L/min. The equipment and facility for the ICB framework is described in sufficient detail to allow biopharmaceutical companies, vendors, contract manufacturers to build or buy their own systems. The design will allow the creation of a global ICB ecosystem that will transform biopharmaceutical manufacturing. The design is fully backward compatible with legacy fed‐batch processes. A clinical production scale is described that can produce smaller batch sizes with the same equipment as that used at the commercial scale. The design described allows the production of as little as 10 g to nearly 35 kg of drug substance per day.

show abstract

“…Appropriate media formulation can also help produce high yields of urokinase. Minor changes in the media formulation, cultural conditions, and physical parameters can affect enzyme production to a great extent (Zhu, Mollet, Hubert, Kyung, & Zhang, 2017). Submerged and solid-state fermentation procedures are famous with respect to urokinase production.…”

Section: Urokinasementioning

confidence: 99%

Production and market comparison of urokinase and streptokinase as effective and cheap fibrinolytic agents for treatment of cardiovascular diseases

Nawaz¹,

Haq

Amin

et al. 2022

Acta Sci Technol

View full text Add to dashboard Cite

Failure of hemostasis and the formation of blood clots in the arteries are the main reasons that provoke the onset of cardiovascular diseases (CVDs) such as myocardial infarction and ischemic stroke. Cardiovascular diseases have become the primary cause of deaths and disabilities across the globe. Therefore, this problem needs to be addressed with urgency. The disintegration of blood clots requires fibrinolytic agents, which are involved in thrombolysis. Streptokinase and urokinase are fibrinolytic enzymes; the former is primarily produced from microbial sources and the latter is isolated from urine, respectively. Streptokinase and urokinase have been in use for a long time to treat cardiovascular diseases. This review explains in detail the comparison of employing streptokinase and urokinase for the said purpose in a cost-effective manner. The recombinant production of both the agents has been discussed in detail. Furthermore, the efficacy of both the agents has been compared based upon their side effects and retention time in the body. A thorough study has been made to compare the influence of using both the agents on the health of cardiovascular patients in the last decade.

show abstract

Industrial Production of Therapeutic Proteins: Cell Lines, Cell Culture, and Purification

Cited by 10 publications

References 67 publications

Animal‐cell culture media: History, characteristics, and current issues

Animal‐cell culture media: History, characteristics, and current issues

The design basis for the integrated and continuous biomanufacturing framework

Production and market comparison of urokinase and streptokinase as effective and cheap fibrinolytic agents for treatment of cardiovascular diseases

Contact Info

Product

Resources

About